IQVIA HOLDINGS INC. Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax
IQVIA HOLDINGS INC. (IQV) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax of -$15.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-19.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax · last filed 2019-02-19
- IQVIA HOLDINGS INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2018 was -$15.00M, a 475.00% decline from fiscal 2017.
- IQVIA HOLDINGS INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2017 was $4.00M, a 83.33% decline from fiscal 2016.
- IQVIA HOLDINGS INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2016 was $24.00M.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 12 month |
|---|---|
| 2018-12-31 | -$15.00M 10-K · filed 2019-02-19 |
| 2017-12-31 | $4.00M 10-K · filed 2019-02-19 |
| 2016-12-31 | $24.00M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |